Esperion Therapeutics (ESPR) Competitors $1.82 -0.03 (-1.35%) Closing price 03:59 PM EasternExtended Trading$1.83 +0.01 (+0.27%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ESPR vs. AAPG, KNSA, DYN, GPCR, ARDX, INDV, NRIX, VIR, SNDX, and ARVNShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Indivior (INDV), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Syndax Pharmaceuticals (SNDX), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Ascentage Pharma Group International Kiniksa Pharmaceuticals Dyne Therapeutics Structure Therapeutics Ardelyx Indivior Nurix Therapeutics Vir Biotechnology Syndax Pharmaceuticals Arvinas Ascentage Pharma Group International (NASDAQ:AAPG) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk. Do analysts rate AAPG or ESPR? Esperion Therapeutics has a consensus target price of $6.75, suggesting a potential upside of 269.86%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in AAPG or ESPR? Esperion Therapeutics received 625 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. CompanyUnderperformOutperformAscentage Pharma Group InternationalN/AN/AEsperion TherapeuticsOutperform Votes62570.15% Underperform Votes26629.85% Is AAPG or ESPR more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Esperion Therapeutics -29.37%N/A -10.77% Does the media refer more to AAPG or ESPR? In the previous week, Esperion Therapeutics had 7 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 9 mentions for Esperion Therapeutics and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.58 beat Esperion Therapeutics' score of -0.31 indicating that Ascentage Pharma Group International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in AAPG or ESPR? 47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, AAPG or ESPR? Ascentage Pharma Group International has higher earnings, but lower revenue than Esperion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group InternationalN/AN/AN/AN/AN/AEsperion Therapeutics$116.33M3.09-$209.25M-$0.64-2.85 SummaryEsperion Therapeutics beats Ascentage Pharma Group International on 8 of the 11 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$359.60M$7.07B$5.81B$9.02BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-2.856.0426.2318.96Price / Sales3.09317.07453.4377.29Price / CashN/A67.8344.0437.47Price / Book-0.476.777.664.69Net Income-$209.25M$138.11M$3.18B$245.69M7 Day Performance-1.88%-1.51%-1.36%-1.85%1 Month Performance-15.12%-1.07%0.73%-1.54%1 Year Performance-30.08%-2.80%17.60%14.60% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics4.4663 of 5 stars$1.83-1.4%$6.75+269.9%-31.0%$359.60M$116.33M-2.85200AAPGAscentage Pharma Group InternationalN/A$18.24+5.7%N/AN/A$1.44BN/A0.00600News CoverageGap UpKNSAKiniksa Pharmaceuticals3.2119 of 5 stars$19.74+0.5%$36.60+85.4%-1.2%$1.43B$270.26M-140.99220Upcoming EarningsDYNDyne Therapeutics3.0828 of 5 stars$13.91-1.0%$49.91+258.8%-38.5%$1.42BN/A-3.91100GPCRStructure Therapeutics2.5083 of 5 stars$24.39+0.1%$81.29+233.3%-46.1%$1.40BN/A-32.96136ARDXArdelyx4.3778 of 5 stars$5.79+2.3%$9.42+62.6%-33.1%$1.37B$124.46M-19.3090Earnings ReportAnalyst ForecastNews CoverageINDVIndivior2.6249 of 5 stars$9.83-2.5%$16.00+62.8%-46.0%$1.36B$1.09B-245.691,164Earnings ReportNews CoverageNRIXNurix Therapeutics1.5889 of 5 stars$17.59+0.1%$31.81+80.9%+68.9%$1.33B$54.55M-6.09300VIRVir Biotechnology3.337 of 5 stars$9.65+0.7%$34.83+261.0%-4.2%$1.33B$86.18M-2.46580Insider TradeSNDXSyndax Pharmaceuticals3.6711 of 5 stars$14.92-1.1%$36.20+142.6%-30.1%$1.27BN/A-4.11110ARVNArvinas3.1093 of 5 stars$18.31+3.6%$60.00+227.7%-63.7%$1.26B$78.50M-3.92420Gap Up Related Companies and Tools Related Companies Ascentage Pharma Group International Competitors Kiniksa Pharmaceuticals Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors Ardelyx Competitors Indivior Competitors Nurix Therapeutics Competitors Vir Biotechnology Competitors Syndax Pharmaceuticals Competitors Arvinas Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESPR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts